Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00837824 · ClinicalTrials.gov registry record · Phase 2
Severe Renal Disease Study in Fabry Patients Treated With Fabrazyme
A Phase 2 study, sponsored by Genzyme, a Sanofi Company.
- Terminated
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT00837824 is a Phase 2 study that was terminated before completion, run by Genzyme, a Sanofi Company. The registered enrollment target is 20 participants.
The verdict
NCT00837824, a Phase 2 study, was terminated before completion, sponsored by Genzyme, a Sanofi Company.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
This study was designed to determine appropriate treatment with Fabrazyme at a biweekly dose of either 1 mg/kg or 3 mg/kg in a population of patients with severe renal disease burden.
Interventions
- BIOLOGICAL Fabrazyme (agalsidase beta)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2002-12 |
| Est. Completion | 2003-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00837824
The ClinicalTrials.gov registry entry for NCT00837824 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genzyme, a Sanofi Company, which has 196 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Fabrazyme (agalsidase beta) is the first listed.
NCT00837824 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00837824 about?
NCT00837824 is a clinical study titled "Severe Renal Disease Study in Fabry Patients Treated With Fabrazyme". This study was designed to determine appropriate treatment with Fabrazyme at a biweekly dose of either 1 mg/kg or 3 mg/kg in a population of patients with severe renal disease burden.
What is the current status of trial NCT00837824?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2002-12. Estimated completion is 2003-08.
What interventions are being tested in trial NCT00837824?
The interventions under investigation include: Fabrazyme (agalsidase beta) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00837824?
This trial is sponsored by Genzyme, a Sanofi Company, which has 196 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.